Page 2,643«..1020..2,6422,6432,6442,645..2,6502,660..»

Stem cells revolutionizing veterinary medicine

Posted: September 25, 2012 at 6:15 am

(WGBA/NBC) - It is a story that gives hope to pet owners all over the country stem cell therapy for animals suffering from problems like arthritis or hip displaysia.

Stem cells are taken out of the dog's fatty tissue are harvested then injected into problem areas leaving the dogs completely healed.

"We couldn't take him on walks, he just laid around a lot," said Keith Nosowiak, Deniro's owner.

"We'd hear whimpering overnight, she'd take a few steps and she would sit down," said Luther Kortbein, Shadow's owner.

Until two months ago, Deniro suffered from severe arthritis, Shadow from hip displaysia.

Deniro's owner thought he may even have to put his German shepherd down.

"We felt we had a decision to make with his quality of life and being in pain we didn't want him to be in pain," Noskowiak said.

Shadow's owner was willing to try anything to cure her.

"Whatever the cost needed to get this done we were willing to do," Kortbein said.

Then Packerland Veterinary Center offered them stem cell therapy by using the dogs own stem cells and then injecting them back into the bloodstream joints.

Read more from the original source:
Stem cells revolutionizing veterinary medicine

Posted in Stem Cell Therapy | Comments Off on Stem cells revolutionizing veterinary medicine

Therapeutic impact of cell transplantation aided by magnetic factor

Posted: September 24, 2012 at 5:13 pm

Public release date: 24-Sep-2012 [ | E-mail | Share ]

Contact: David Eve celltransplantation@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (Sept. 24, 2012) Two studies in the current issue of Cell Transplantation (21:6), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, demonstrate how the use of magnetic particles are a factor that can positively impact on the targeted delivery of transplanted stem cells and to also provide better cell retention.

A research team from the University of British Columbia used focused magnetic stem cell targeting to improve the delivery and transport of mensenchymal stem cells to the retinas of test rats while researchers from Cedars-Sinai Heart Institute (Los Angeles) injected magnetically enhanced cardiac stem cells to guide the cells to their target to increase cell retention and therapeutic benefit in rat models of ischemic/reperfusion injury.

According to study co-author Dr. Kevin Gregory-Evans, MD, PhD, of the Centre for Macular Degeneration at the University of British Columbia, degeneration of the retina - the cause of macular degeneration as well as other eye diseases - accounts for most cases of blindness in the developed world. To date, the transplantation of mensenchymal stem cells to the damaged retina has had "limited success" because the cells reaching the retina have been in "very low numbers and in random distribution."

Seeking to improve stem cell transplantation to the retina, the researchers magnetized rat mesenchymal stem cells (MSCs) using superparamagnetic iron oxide nanoparticles (SPIONs). Via an externally placed magnet, they directed the SPION enhanced cells to the peripheral retinas of the test animals.

"Our results showed that large numbers of blood-borne magnetic MSCs can be targeted to specific retinal locations and produce therapeutically useful biochemical changes in the target tissue," explained Gregory-Evans. "Such an approach would be optimal in focal tissue diseases of the outer retina, such as age-related macular degeneration."

Contact:

Dr. Kevin Gregory-Evans, Centre for Macular Research, Department of Ophthalmology and Visual Sciences, University of British Columbia, 2550 Willow St., Vancouver, BC, Canada, V5Z 3N9 Tel. + 1-604-671-0419 Fax. + 1-604-875-4663 Email: kge30@interchange.unc.ca

Citation: Yanai, A.; Hfeli, U. O.; Metcalfe, A. L.; Soema, P.; Addo, L.; Gregory-Evans, C. Y.; Po, K.; Shan, X.; Moritz, O. L.; Gregory-Evans, K. Focused Magnetic Stem Cell Targeting to the Retina Using Superparamagnetic Iron Oxide Nanoparticles. Cell Transplant. 21(6):1137-1148; 2012.

Read this article:
Therapeutic impact of cell transplantation aided by magnetic factor

Posted in Stem Cells | Comments Off on Therapeutic impact of cell transplantation aided by magnetic factor

Cancer Stem Cells Drug Pipeline Update 2012

Posted: September 24, 2012 at 5:13 pm

NEW YORK, Sept. 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Stem Cells Drug Pipeline Update 2012

http://www.reportlinker.com/p0980850/Cancer-Stem-Cells-Drug-Pipeline-Update-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells.

There are today 203 companies plus partners developing 243 cancer stem cells and developmental pathways drugs in 684 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 123 drugs. Cancer Stem Cells Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 165 different targets. These targets are further categorized on in the software application by 38 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.

How May Drug Pipeline Update Be of Use?

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

* Find competitors, collaborations partners, M&A candidates etc.

* Jump start competitive drug intelligence operations

* Excellent starting point for world wide benchmarking

View original post here:
Cancer Stem Cells Drug Pipeline Update 2012

Posted in Stem Cells | Comments Off on Cancer Stem Cells Drug Pipeline Update 2012

Reproducing Research Results: Removing a Scientific Roadblock

Posted: September 23, 2012 at 3:55 pm


The California stem cell agency faces
no easy task in trying to translate basic research findings into
something that can be used to treat patients and be sold commercially.

Even clinical trials, which only begin
long after the basic research is done and which involve more ordinary
therapeutic treatments than stem cells, fail at an astonishing rate.
Only one out of five that enter the clinical trial gauntlet
successfully finish the second stage, according to industry data
cited last spring by Pat Olson, executive director of scientific activities at the stem cell agency. And
then come even more challenges.
But at a much earlier stage of
research there is the “problem of irreproducible results,” in the
words of writer Monya Baker of the journal Nature. Baker last month reported on
moves by a firm called Science Exchange in Palo Alto, Ca., to
do something to ease the problem and speed up preclinical research.
The effort is called the Reproducibility Initiative and also involves
PLOS and figshare, an open science Internet project.
Elizabeth Iorns
Science Exchange Photo
Science Exchange is headed by Elizabeth
Iorns
, a scientist and co-founder of the firm. She wrote about  test-tube-to-clinic translation issues in a recent article in New
Scientist
that was headlined, “Is medical science built on shaky
foundations?”
Iorns said,

“One goal of scientific publication
is to share results in enough detail to allow other research teams to
reproduce them and build on them. However, many recent reports have
raised the alarm that a shocking amount of the published literature
in fields ranging from cancer biology to psychology is not
reproducible.”

Iorns cited studies in Nature that
reported that Bayer cannot “replicate about two-thirds of published
studies identifying possible drug targets” and that Amgen failed at
even a higher rate. It could not “replicate 47 of 53 highly
promising results they examined.”
The California Stem Cell Report earlier
this week asked Iorns for her thoughts on the implications for the
California stem cell agency, whose motto is "Turning stem cells into cures." Here is the full text of her response.

“First, I think it is important to
accept that there is a crisis affecting preclinical research. Recent
studies estimate that 70% of preclinical research cannot be
reproduced. This is the research that should form the foundation upon
which new discoveries can be made to enhance health, lengthen life,
and reduce the burdens of illness and disability. The
irreproducibility of preclinical research is a significant impediment
to the achievement of these goals. To solve this problem requires
immediate and concrete action. It is not enough to make
recommendations and issue guidelines to researchers. Funders must act
to ensure they fund researchers to produce high quality reproducible
research. One such way to do so, is to reward, or require,
independent validation of results. The reproducibility initiative
provides a mechanism for independent validation, allowing the
identification of high quality reproducible research. It is vital
that funders act now to address this problem, to prevent the wasted
time and money that is currently spent funding non-reproducible
research and to prevent the erosion of public trust and support for
research.”

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Reproducing Research Results: Removing a Scientific Roadblock

Reproducing Research Results: Removing a Scientific Roadblock

Posted: September 23, 2012 at 3:54 pm


The California stem cell agency faces
no easy task in trying to translate basic research findings into
something that can be used to treat patients and be sold commercially.

Even clinical trials, which only begin
long after the basic research is done and which involve more ordinary
therapeutic treatments than stem cells, fail at an astonishing rate.
Only one out of five that enter the clinical trial gauntlet
successfully finish the second stage, according to industry data
cited last spring by Pat Olson, executive director of scientific activities at the stem cell agency. And
then come even more challenges.
But at a much earlier stage of
research there is the “problem of irreproducible results,” in the
words of writer Monya Baker of the journal Nature. Baker last month reported on
moves by a firm called Science Exchange in Palo Alto, Ca., to
do something to ease the problem and speed up preclinical research.
The effort is called the Reproducibility Initiative and also involves
PLOS and figshare, an open science Internet project.
Elizabeth Iorns
Science Exchange Photo
Science Exchange is headed by Elizabeth
Iorns
, a scientist and co-founder of the firm. She wrote about  test-tube-to-clinic translation issues in a recent article in New
Scientist
that was headlined, “Is medical science built on shaky
foundations?”
Iorns said,

“One goal of scientific publication
is to share results in enough detail to allow other research teams to
reproduce them and build on them. However, many recent reports have
raised the alarm that a shocking amount of the published literature
in fields ranging from cancer biology to psychology is not
reproducible.”

Iorns cited studies in Nature that
reported that Bayer cannot “replicate about two-thirds of published
studies identifying possible drug targets” and that Amgen failed at
even a higher rate. It could not “replicate 47 of 53 highly
promising results they examined.”
The California Stem Cell Report earlier
this week asked Iorns for her thoughts on the implications for the
California stem cell agency, whose motto is "Turning stem cells into cures." Here is the full text of her response.

“First, I think it is important to
accept that there is a crisis affecting preclinical research. Recent
studies estimate that 70% of preclinical research cannot be
reproduced. This is the research that should form the foundation upon
which new discoveries can be made to enhance health, lengthen life,
and reduce the burdens of illness and disability. The
irreproducibility of preclinical research is a significant impediment
to the achievement of these goals. To solve this problem requires
immediate and concrete action. It is not enough to make
recommendations and issue guidelines to researchers. Funders must act
to ensure they fund researchers to produce high quality reproducible
research. One such way to do so, is to reward, or require,
independent validation of results. The reproducibility initiative
provides a mechanism for independent validation, allowing the
identification of high quality reproducible research. It is vital
that funders act now to address this problem, to prevent the wasted
time and money that is currently spent funding non-reproducible
research and to prevent the erosion of public trust and support for
research.”

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Reproducing Research Results: Removing a Scientific Roadblock

Probe sought into status of stem cell therapy in the Philippines

Posted: September 23, 2012 at 12:11 pm

The World News (WN) Network, has created this privacy statement in order to demonstrate our firm commitment to user privacy. The following discloses our information gathering and dissemination practices for wn.com, as well as e-mail newsletters.

We do not collect personally identifiable information about you, except when you provide it to us. For example, if you submit an inquiry to us or sign up for our newsletter, you may be asked to provide certain information such as your contact details (name, e-mail address, mailing address, etc.).

When you submit your personally identifiable information through wn.com, you are giving your consent to the collection, use and disclosure of your personal information as set forth in this Privacy Policy. If you would prefer that we not collect any personally identifiable information from you, please do not provide us with any such information. We will not sell or rent your personally identifiable information to third parties without your consent, except as otherwise disclosed in this Privacy Policy.

Except as otherwise disclosed in this Privacy Policy, we will use the information you provide us only for the purpose of responding to your inquiry or in connection with the service for which you provided such information. We may forward your contact information and inquiry to our affiliates and other divisions of our company that we feel can best address your inquiry or provide you with the requested service. We may also use the information you provide in aggregate form for internal business purposes, such as generating statistics and developing marketing plans. We may share or transfer such non-personally identifiable information with or to our affiliates, licensees, agents and partners.

We may retain other companies and individuals to perform functions on our behalf. Such third parties may be provided with access to personally identifiable information needed to perform their functions, but may not use such information for any other purpose.

In addition, we may disclose any information, including personally identifiable information, we deem necessary, in our sole discretion, to comply with any applicable law, regulation, legal proceeding or governmental request.

We do not want you to receive unwanted e-mail from us. We try to make it easy to opt-out of any service you have asked to receive. If you sign-up to our e-mail newsletters we do not sell, exchange or give your e-mail address to a third party.

E-mail addresses are collected via the wn.com web site. Users have to physically opt-in to receive the wn.com newsletter and a verification e-mail is sent. wn.com is clearly and conspicuously named at the point of

If you no longer wish to receive our newsletter and promotional communications, you may opt-out of receiving them by following the instructions included in each newsletter or communication or by e-mailing us at michaelw(at)wn.com

The security of your personal information is important to us. We follow generally accepted industry standards to protect the personal information submitted to us, both during registration and once we receive it. No method of transmission over the Internet, or method of electronic storage, is 100 percent secure, however. Therefore, though we strive to use commercially acceptable means to protect your personal information, we cannot guarantee its absolute security.

The rest is here:
Probe sought into status of stem cell therapy in the Philippines

Posted in Stem Cell Therapy | Comments Off on Probe sought into status of stem cell therapy in the Philippines

Solon urges Congress to conduct cursory check on the status of stem cell therapy in the country (15966897)

Posted: September 22, 2012 at 6:12 pm

According to Aristotle, only the Pentacosiomedimnoi were eligible for election to high office as archons and therefore only they gained admission into the Areopagus. A modern view affords the same privilege to the hippeis. The top three classes were eligible for a variety of lesser posts and only the Thetes were excluded from all public office.

Depending on how we interpret the historical facts known to us, Solon's constitutional reforms were either a radical anticipation of democratic government, or they merely provided a plutocratic flavour to a stubbornly aristocratic regime, or else the truth lies somewhere between these two extremes.

Solon's reforms can thus be seen to have taken place at a crucial period of economic transition, when a subsistence rural economy increasingly required the support of a nascent commercial sector. The specific economic reforms credited to Solon are these: Fathers were encouraged to find trades for their sons; if they did not, there would be no legal requirement for sons to maintain their fathers in old age. Foreign tradesmen were encouraged to settle in Athens; those who did would be granted citizenship, provided they brought their families with them. Cultivation of olives was encouraged; the export of all other produce was prohibited. Competitiveness of Athenian commerce was promoted through revision of weights and measures, possibly based on successful standards already in use elsewhere, such as Aegina or Euboia or, according to the ancient account but unsupported by modern scholarship, Argos

It is generally assumed, on the authority of ancient commentators that Solon also reformed the Athenian coinage. However, recent numismatic studies now lead to the conclusion that Athens probably had no coinage until around 560 BC, well after Solon's reforms.

Solon's economic reforms succeeded in stimulating foreign trade. Athenian black-figure pottery was exported in increasing quantities and good quality throughout the Aegean between 600 BC and 560 BC, a success story that coincided with a decline in trade in Corinthian pottery. The ban on the export of grain might be understood as a relief measure for the benefit of the poor. However, the encouragement of olive production for export could actually have led to increased hardship for many Athenians since it would have led to a reduction in the amount of land dedicated to grain. Moreover an olive produces no fruit for the first six years. The real motives behind Solon's economic reforms are therefore as questionable as his real motives for constitutional reform. Were the poor being forced to serve the needs of a changing economy, or was the economy being reformed to serve the needs of the poor?

Solon's reform of these injustices was later known and celebrated among Athenians as the Seisachtheia (shaking off of burdens). As with all his reforms, there is considerable scholarly debate about its real significance. Many scholars are content to accept the account given by the ancient sources, interpreting it as a cancellation of debts, while others interpret it as the abolition of a type of feudal relationship, and some prefer to explore new possibilities for interpretation. prohibition on a debtor's person being used as security for a loan. release of all Athenians who had been enslaved.

The removal of the horoi clearly provided immediate economic relief for the most oppressed group in Attica, and it also brought an immediate end to the enslavement of Athenians by their countrymen. Some Athenians had already been sold into slavery abroad and some had fled abroad to escape enslavement Solon proudly records in verse the return of this diaspora. It has been cynically observed, however, that few of these unfortunates were likely to have been recovered. It has been observed also that the seisachtheia not only removed slavery and accumulated debt, it also removed the ordinary farmer's only means of obtaining further credit.

The seisachtheia however was merely one set of reforms within a broader agenda of moral reformation. Other reforms included: the abolition of extravagant dowries. legislation against abuses within the system of inheritance, specifically with relation to the epikleros (i.e. a female who had no brothers to inherit her father's property and who was traditionally required to marry her nearest paternal relative in order to produce an heir to her father's estate). entitlement of any citizen to take legal action on behalf of another. the disenfranchisement of any citizen who might refuse to take up arms in times of civil strife, a measure that was intended to counteract dangerous levels of political apathy.

The personal modesty and frugality of the rich and powerful men of Athens in the city's subsequent golden age have been attested to by Demosthenes. Perhaps Solon, by both personal example and legislated reform, established a precedent for this decorum. A heroic sense of civic duty later united Athenians against the might of the Persians. Perhaps this public spirit was instilled in them by Solon and his reforms. Also see Solon and Athenian sexuality

The literary merit of Solon's verse is generally considered unexceptional. Solon the poet can be said to appear 'self-righteous' and 'pompous' at times and he once composed an elegy with moral advice for a more gifted elegiac poet, Mimnermus. Most of the extant verses show him writing in the role of a political activist determined to assert personal authority and leadership and they have been described by the German classicist Wilamowitz as a "versified harangue" (Eine Volksrede in Versen). According to Plutarch however, Solon originally wrote poetry for amusement, discussing pleasure in a popular rather than philosophical way. Solon's elegiac style is said to have been influenced by the example of Tyrtaeus. He also wrote iambic and trochaic verses which, according to one modern scholar, are more lively and direct than his elegies and possibly paved the way for the iambics of Athenian drama.

See more here:
Solon urges Congress to conduct cursory check on the status of stem cell therapy in the country (15966897)

Posted in Cell Therapy | Comments Off on Solon urges Congress to conduct cursory check on the status of stem cell therapy in the country (15966897)

Solon urges Congress to conduct cursory check on the status of stem cell therapy in the country (15966897)

Posted: September 22, 2012 at 8:14 am

According to Aristotle, only the Pentacosiomedimnoi were eligible for election to high office as archons and therefore only they gained admission into the Areopagus. A modern view affords the same privilege to the hippeis. The top three classes were eligible for a variety of lesser posts and only the Thetes were excluded from all public office.

Depending on how we interpret the historical facts known to us, Solon's constitutional reforms were either a radical anticipation of democratic government, or they merely provided a plutocratic flavour to a stubbornly aristocratic regime, or else the truth lies somewhere between these two extremes.

Solon's reforms can thus be seen to have taken place at a crucial period of economic transition, when a subsistence rural economy increasingly required the support of a nascent commercial sector. The specific economic reforms credited to Solon are these: Fathers were encouraged to find trades for their sons; if they did not, there would be no legal requirement for sons to maintain their fathers in old age. Foreign tradesmen were encouraged to settle in Athens; those who did would be granted citizenship, provided they brought their families with them. Cultivation of olives was encouraged; the export of all other produce was prohibited. Competitiveness of Athenian commerce was promoted through revision of weights and measures, possibly based on successful standards already in use elsewhere, such as Aegina or Euboia or, according to the ancient account but unsupported by modern scholarship, Argos

It is generally assumed, on the authority of ancient commentators that Solon also reformed the Athenian coinage. However, recent numismatic studies now lead to the conclusion that Athens probably had no coinage until around 560 BC, well after Solon's reforms.

Solon's economic reforms succeeded in stimulating foreign trade. Athenian black-figure pottery was exported in increasing quantities and good quality throughout the Aegean between 600 BC and 560 BC, a success story that coincided with a decline in trade in Corinthian pottery. The ban on the export of grain might be understood as a relief measure for the benefit of the poor. However, the encouragement of olive production for export could actually have led to increased hardship for many Athenians since it would have led to a reduction in the amount of land dedicated to grain. Moreover an olive produces no fruit for the first six years. The real motives behind Solon's economic reforms are therefore as questionable as his real motives for constitutional reform. Were the poor being forced to serve the needs of a changing economy, or was the economy being reformed to serve the needs of the poor?

Solon's reform of these injustices was later known and celebrated among Athenians as the Seisachtheia (shaking off of burdens). As with all his reforms, there is considerable scholarly debate about its real significance. Many scholars are content to accept the account given by the ancient sources, interpreting it as a cancellation of debts, while others interpret it as the abolition of a type of feudal relationship, and some prefer to explore new possibilities for interpretation. prohibition on a debtor's person being used as security for a loan. release of all Athenians who had been enslaved.

The removal of the horoi clearly provided immediate economic relief for the most oppressed group in Attica, and it also brought an immediate end to the enslavement of Athenians by their countrymen. Some Athenians had already been sold into slavery abroad and some had fled abroad to escape enslavement Solon proudly records in verse the return of this diaspora. It has been cynically observed, however, that few of these unfortunates were likely to have been recovered. It has been observed also that the seisachtheia not only removed slavery and accumulated debt, it also removed the ordinary farmer's only means of obtaining further credit.

The seisachtheia however was merely one set of reforms within a broader agenda of moral reformation. Other reforms included: the abolition of extravagant dowries. legislation against abuses within the system of inheritance, specifically with relation to the epikleros (i.e. a female who had no brothers to inherit her father's property and who was traditionally required to marry her nearest paternal relative in order to produce an heir to her father's estate). entitlement of any citizen to take legal action on behalf of another. the disenfranchisement of any citizen who might refuse to take up arms in times of civil strife, a measure that was intended to counteract dangerous levels of political apathy.

The personal modesty and frugality of the rich and powerful men of Athens in the city's subsequent golden age have been attested to by Demosthenes. Perhaps Solon, by both personal example and legislated reform, established a precedent for this decorum. A heroic sense of civic duty later united Athenians against the might of the Persians. Perhaps this public spirit was instilled in them by Solon and his reforms. Also see Solon and Athenian sexuality

The literary merit of Solon's verse is generally considered unexceptional. Solon the poet can be said to appear 'self-righteous' and 'pompous' at times and he once composed an elegy with moral advice for a more gifted elegiac poet, Mimnermus. Most of the extant verses show him writing in the role of a political activist determined to assert personal authority and leadership and they have been described by the German classicist Wilamowitz as a "versified harangue" (Eine Volksrede in Versen). According to Plutarch however, Solon originally wrote poetry for amusement, discussing pleasure in a popular rather than philosophical way. Solon's elegiac style is said to have been influenced by the example of Tyrtaeus. He also wrote iambic and trochaic verses which, according to one modern scholar, are more lively and direct than his elegies and possibly paved the way for the iambics of Athenian drama.

Here is the original post:
Solon urges Congress to conduct cursory check on the status of stem cell therapy in the country (15966897)

Posted in Stem Cell Therapy | Comments Off on Solon urges Congress to conduct cursory check on the status of stem cell therapy in the country (15966897)

Immortality and 3 Stem Cell Research Stocks

Posted: September 21, 2012 at 9:20 pm

By Karen Rogers - September 21, 2012 | Tickers: BAX, NBS, OSIR | 0 Comments

Karen is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited.

Stem cell research puts immortality in our hands. By medically treating stem cells to repair damaged organs, one could, in theory, live forever. The following three stem cell research companies are achingly close to perfecting techniques that will repair and strengthen damaged human hearts.

Osiris Therapeutics (NASDAQ: OSIR) Prochymal is the only drug thats been granted fast track status and Orphan Drug status by the FDA. Already in Phase III clinical evaluations, Prochymal repairs heart tissue damaged by a heart attack and it is also under evaluation for Chronic Obstructive Pulmonary Disease.

Osiris biologic drugs utilize either human mesenchymal stem cells (MSC) or stem cells taken from adult bone marrow to avoid the ethical controversy surrounding embryonic or fetal stem cell research usage. MSC are taken directly from the donors human bone marrow and one single donation can produce up to 10,000 treatments. Osiris has designed their treatment to be universally accepted by all recipients to eliminate rejection problems. This treatment can be frozen and kept at end-user medical facilities until it is needed.

Osiris has a market cap of $312.25 million and a P/E ratio of 93.14, which far exceeds the S&P 500 P/E ratio of 17.7. The stock is up 77.57% over the past 52 weeks, and closed at $9.50 this past Friday. Osiris has cash of $38.75 million, zero debt, and operating cash flow of -$17.47 million. The company reports $27.92 million in revenue, and net income of $3.53 million for this year. Analysts following Osiris rate it a strong buy/buy.

Neostem (NYSEMKT: NBS) is developing AMR-1000, a stem cell therapy designed to rebuild heart tissue damaged after a heart attack that has also shown promise in treating congestive heart failure. For the first time, a U.S. patent has been issued to Neostem for their Compositions and Methods of Vascular Injury Repair, to protect the treatment and the delivery method.

The company offers consumers the opportunity to store their own stem cells for future treatment. During a four-hour collection process, adult stem cells are harvested from the circulating blood. Fifty-percent of the stem cells are stored in immune reconstitution bags to be used for stem cell treatable cancers or immune system transplants. The remaining cells are stored in separate containers for future use as new stem cell treatments are developed.

Neostem has a market cap of $106.32 million and a P/E ratio of -1.64%. The stock is up 9.38% over the past 52 weeks, and closed at $0.69 this past Friday. Neostem has cash of $2.12 million, debt of $3.75 million, and operating cash of -$8.51 million. The company has earned revenue of $77.20 million and net income of -$42.64 million this year. Of the 3 analysts following Neostem, 2 rate it a strong buy and 1 rates it as buy.

Earlier this year, Baxter Internationals (NYSE: BAX) CD34+ entered Phase III trials, a stem cell treatment designed to strengthen the heart by increasing exercise capacity and reducing angina attacks due to chronic myocardial ischemia. This autologous stem cell therapy harvests the cells from the donors bone marrow, and everything but the stem cells is returned to the donor.

Here is the original post:
Immortality and 3 Stem Cell Research Stocks

Posted in Stem Cell Research | Comments Off on Immortality and 3 Stem Cell Research Stocks

Einstein Hosts Its First Stem Cell Institute Symposium

Posted: September 21, 2012 at 9:20 pm

Newswise September 21, 2012 (BRONX, NY) The promise of stem cells seems limitless. If they can be coaxed into rebuilding organs, repairing damaged spinal cords and restoring ravaged immune systems, these malleable cells would revolutionize medical treatment. But stem cell research is still in its infancy, as scientists seek to better understand the role of these cells in normal human development and disease.

On Friday, September 14, the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research at Albert Einstein College of Medicine of Yeshiva University offered the Einstein community and invited guests an opportunity to hear from leading stem cell scientists investigating the dynamic field. The 2012 Einstein Stem Cell Institute Symposium featured speakers from around the globe presenting the latest research on induced pluripotent stem cells (iPS cells), cell reprogramming, as well as cancer and hematopoietic (blood-forming) stem cells.

This symposium was an important milestone for stem cell research at Einstein and confirms our intent to contribute to advances in stem cell biology, said the events host and organizer, Paul Frenette, M.D., director and chair of Einsteins Stem Cell Institute and professor of medicine and of cell biology.

There has been a lot of hype in the past few years about the promise of stem cell research and some concerns that perhaps it was oversold to the public, said Dr. Frenette. The symposiums speakers nicely illustrated the tremendous progress that has been made thus far and showed how outstanding research is helping us to realize the full potential of stem cells.

The afternoon event included four presentations: George Q. Daley, M.D., Ph.D., discussed Lin28 in Stem Cells and Disease. Dr. Daley is the Samuel E. Lux IV Professor of Hematology/Oncology and director of the Stem Cell Transplantation Program at Boston Childrens Hospital; professor of biological chemistry and molecular pharmacology, of medicine, and of pediatrics at Harvard Medical School; and an investigator of the Howard Hughes Medical Institute.

Kathrin Plath, Ph.D., gave a talk on the Mechanisms of Reprogramming of Pluripotency. Dr. Plath is associate professor of biological chemistry at the University of California, Los Angeless David Geffen School of Medicine.

Toshio Suda, M.D., Ph.D., professor of cell differentiation at the Graduate School of Medicine, Keio University in Tokyo, Japan, presented Hematopoietic Stem Cells in Hypoxic Niches.

Andreas Trumpp, Ph.D., professor and head of the division of stem cells and cancer, and managing director of the Heidelberg Institute for Stem Cell Technology and Experimental Medicine in Heidleberg, Germany, discussed Circulating Metastasis-initiating Cells in Breast Cancer.

Dr. Frenette closed the event by thanking the speakers and the 100 attendees in the Ethel and Samuel J. LeFrak Auditorium, as well as additional attendees viewing the proceedings from overflow rooms in Einsteins Michael F. Price Center for Genetic and Translational Medicine/Harold and Muriel Block Research Pavilion.

We hope this symposium will foster collaborations between Einstein faculty members and leaders in the field, and embolden our developing program toward new heights of research excellence, said Dr. Frenette.

Read more from the original source:
Einstein Hosts Its First Stem Cell Institute Symposium

Posted in Stem Cell Research | Comments Off on Einstein Hosts Its First Stem Cell Institute Symposium

Page 2,643«..1020..2,6422,6432,6442,645..2,6502,660..»